March 27, 2015
March 04, 2015
March 03, 2015
A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.
EntreMed leverages best of China and the West and seeks to expand pipeline.
Phase II Study of Oral ENMD-2076 Administered to Patients (pts) With Advanced Soft Tissue Sarcoma
Phase II Study of Oral ENMD-2076 Administered to Patients with Ovarian Clear Cell Carcinoma